Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by macman1519on Feb 06, 2018 2:19pm

72 Views

Post# 27512780

RE:Rutherrin for Phase II?

Good questions, but Roger aint talkin as usual!!!!!

fredgoodwinson wrote:
Rutherrin had been branded and trademarked by the 23rd of February 2015 so the MSAB would certainly have been aware of it when determining the Clinical Protocol for the current NMIBC Trial. More effective and less toxic than TLD1433 alone so something of a mystery as to why it wasn`t deployed. Can only think that it was rejected by Health Canada at the pre Clinical Trial Application meeting announced on the 2nd of April 2015?

Could it be considered for Phase II given that 2 of the first 4 showed inflammation and since it has now been earmarked for Trials elsewhere?

It might make all the difference to outcomes and in preventing further damaging delays to the Trial process.